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Bilirubin-IX-alpha (BR) is the ﬁnal product of heme metabolism through the heme oxyge-
nase/biliverdin reductase (HO/BVR) system. Previous papers reported on the microbicidal
effects of the HO by-products biliverdin-IX-alpha, carbon monoxide and iron, through either
direct or indirect mechanisms. In this paper the evidence of a virucidal effect of BR against
human herpes simplex virus type 1 (HSV-1) and the enterovirus EV71 was provided.
Bilirubin-IX-alpha, at concentrations 1–10μM, close to those found in blood and tissues,
signiﬁcantly reduced HSV-1 and EV71 replication in Hep-2 and Vero cell lines, respectively.
Bilirubin-IX-alpha inhibited viral infection of Hep-2 andVero cells when given 2 h before, con-
comitantly and 2 h after viral infection. Furthermore, BR retained its antiviral activity even
complexed with a saturating concentration of human serum-albumin. Moreover, 10μM BR
increased the formation of nitric oxide and the phosphorylation of c-Jun N-terminal kinase
in Vero and Hep-2 cell lines, respectively, thus implying a role of these two pathways in
the mechanism of antiviral activity of the bile pigment. In conclusion, these results support
the antiviral effect of BR against HSV-1 and enterovirus in vitro, and put the basis for fur-
ther basic and clinical studies to understand the real role of BR as an endogenous antiviral
molecule.
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INTRODUCTION
The heme oxygenase/biliverdin reductase (HO/BVR) axis is the
main metabolic pathway by which heme is degraded. The com-
bined action of these enzymes converts heme into ferrous iron
(FeII), carbon monoxide (CO), and biliverdin-IX-alpha (BV)
which is the precursor of bilirubin-IX-alpha (BR; Maines, 1997;
Mancuso and Barone, 2009). For several years, the by-products
of the HO/BVR axis were considered mere waste products, but
over the past two decades, a number of investigators have focused
their attention on both HO/BVR and their products in an attempt
to elucidate their true biological functions. Stocker et al. (1987b)
described the antioxidant properties of BR, and 6 years laterVerma
et al. (1993) proposed a role for CO as an endogenous neuro-
modulator. These observations were followed by numerous papers
demonstrating CO’s important role as a regulator of synaptic
transmission, cardiac function, and vessel tone (Wu and Wang,
2005). Bilirubin-IX-alpha helps maintain the cell’s redox equi-
librium by activating important pro-survival signaling pathways,
such as those involving the proto-oncogene Akt or the mitogen-
activated protein kinase family (MAPK), and by scavenging reac-
tive oxygen and nitrogen species (ROS and RNS, respectively;
Stocker et al., 1987b; Minetti et al., 1998; Kaur et al., 2003; Man-
cuso et al., 2006b, 2008). These ﬁndings suggest that up-regulation
of the HO/BVR axis is a useful mechanism for improving cells’
responses to stress, and substances known to increase HO activity
in vitro are being explored as potential drugs for the treatment
of free radical-induced diseases (Mancuso and Barone, 2009). In
addition, the up-regulation of HO was shown to play an impor-
tant role against bacterial and viral infections. The overexpression
of the inducible isoform of HO (HO-1) displayed a signiﬁcant
antiviral activity against enterovirus and hepatitis viruses (Zhu
et al., 2010; Tung et al., 2011). With regard to the by-products of
the HO system involved in this antiviral activity, BV was shown to
interfere with human hepatitis C virus (HCV) and human herpes
virus (HHV)-6 replication as well as to reduce the cytopathic effect
of human immunodeﬁciency type 1 virus (HIV) in Huh or MT-
4 cells (Mori et al., 1991; Nakagami et al., 1992; Lehmann et al.,
2010; Zhu et al., 2010). In addition, CO inhibited the growth of
enterovirus, E. coli, P. aeruginosa as well as S. aureus (Nobre et al.,
2007; Tung et al., 2011; Desmard et al., 2012) and iron almost
completely decreased HCV core mRNA and protein (Hou et al.,
2009). Taken together these results underlined amajor role forHO
in antiviral and antibacterial defense. That said, it is noteworthy
to mention that no data are available to date about the potential
antiviral activity of BRproduced byBVR.Asmentioned before,BR
was shown to serve as an efﬁcient scavenger for ROSwhich, in turn,
are currently viewed as effectors of the antimicrobial activity of the
immune response (Bogdan et al., 2000; Fang, 2004; Fialkow et al.,
2007), therefore a direct antiviral role for BR is unlikely. On the
other hand, recent ﬁndings demonstrated alternative mechanisms
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for the cytoprotective activity of BR, including the stimulation of
nitric oxide (NO) release and themodulation of theMAPK system
in pheochromocytoma cells and primary cultures of rat cerebel-
lar granules (Mancuso et al., 2008). NO plays an important role
in the antiviral defense (Croen, 1993; Akaike and Maeda, 2000)
and it is also an intermediate in the bactericidal activity of certain
drugs (Timmins et al., 2004; Koide et al., 2009). Moreover, the up-
regulation of speciﬁc MAPK, such as the c-Jun N-terminal kinase
(JNK), was shown to increase the cytoprotective defense against
viruses (Hrincius et al., 2010).
The aim of this work was to explore the antiviral activity of BR
in vitro and the plausible intracellular systems involved in this pro-
tective effect. Since intracellular BR exists in the free form whereas
in the bloodstream the bile pigment is bound to human serum-
albumin (HSA), the antiviral activity of both BR and BR–HSA
were studied. The viral species against which BR and BR–HSA
were tested are the human herpes simplex type 1 virus (HSV-
1), a DNA virus which belong to the Herpesviridae family, and
enterovirus 71 (EV71) which belong to the Picornaviridae family
(RNA viruses). Both these viruses are responsible for important
acute and chronic diseases in humans.
MATERIALS AND METHODS
CHEMICALS AND ANTIBODIES
All chemicals were purchased from Sigma-Aldrich (St. Louis,
MO, USA) unless otherwise stated. Bilirubin-IX-alpha (Frontier
Scientiﬁc, Carnforth, Lancashire, UK) was dissolved in sodium
hydroxide (0.1M) at a concentration of 10mMand further diluted
in double-distilled water. Bilirubin-IX-alpha solution was freshly
prepared before each experiment and protected from light. The
formation of the BR–HSA complex, at saturating concentra-
tions of the protein, was allowed by incubating BR and HSA
for 10min at 37˚C in the dark at a ratio up to 1:2 (Mancuso
et al., 2006a). The ﬂuorescent cell-permeant dye 4-amino-5-
methylamino-2′,7′-diﬂuoroﬂuorescein (DAF-FM) diacetate was
purchased fromMolecular Probes (InvitrogenCarlsbad,CA,USA)
and the JNK inhibitor SP600125 was from Assay Design (Enzo
Life Sciences International, Inc., Plymouth Meeting, PA, USA).
Anti-pJNK Thr183/Tyr185, antibody was purchased from Cell
Signaling, (Danvers, MA, USA) and the anti-α-tubulin rabbit
monoclonal antibody was from Thermo Scientiﬁc (Rockford, IL,
USA).
CELL CULTURE AND VIRUS PROPAGATION
The human laryngeal carcinoma cell line (Hep-2) and African
green monkey kidney epithelial cells line (Vero) were maintained
in Minimum-Essential-Medium (MEM) additioned with 10%
fetal calf serum (FCS), glutamine (200mM), penicillin (100U/ml)
and streptomycin (100μg/ml). Human herpes simplex virus type
1 (KOS strain) and EV71 were purchased from the ATCC (Milan,
Italy) and propagated and titrated in Hep-2 andVero cells, respec-
tively. The virus titre for both HSV-1 and EV71 was calculated by
the plaque assay (Saijets et al., 2003; Hung et al., 2010).
The day before the experiment, 1× 105 Hep-2 orVero cells were
seeded in 24-multiwell plates at a density of 400 cells/mm2. After
overnight incubation, cells were treated withHSV-1 or EV71 alone
or in the presence of test substances as described in Protocols 1–4.
STUDY DESIGN
In order to mimic the different conditions during which BR
could interfere with viral infectivity, four different protocols were
designed.
Protocol 1
Hep-2 and Vero cells were pre-incubated with BR (1–10μM) for
2 h. At the end of incubation, the BR-containing medium was
discarded, replaced with fresh medium and the cells infected with
HSV-1 and EV71. After 2 h, the inocula were removed and the cells
incubated in fresh culture medium for 24–48 h. These time points
were selected considering the replication cycles of bothHSV-1 and
enterovirus which are 10–20 h.
Protocol 2
Herpes simplex virus type 1 and EV71 were pre-incubated with
BR (1–10μM) alone or complexed with saturating HSA (20μM)
for 1 h and then transferred to Hep-2 and Vero monolayers for
the infection. After 2 h, the inocula were removed and the cells
incubated in fresh culture medium for 24–48 h. The effect of HSA
per se on viral replication was also evaluated by incubating either
HSV-1 or EV71with 20μMHSAand then transferring the inocula
to Hep-2 and Vero cells as described above.
Protocol 3
Hep-2 andVero cells were exposed to BR (1–10μM) alone or com-
plexed with saturating HSA (20μM) and concomitantly infected
withHSV-1 and EV71 for 2 h.At the end of incubation, the inocula
were removed and the cells incubated in fresh culture medium for
24–48 h. The antiviral effect of HSA per se was also evaluated by
infecting Hep-2 and Vero cells with either HSV-1 or EV71 in the
presence of 20μM HSA as described above.
Protocol 4
After 2 h of infection with HSV-1 and EV71, the inocula were
removed and Hep-2 and Vero monolayers treated with BR (1–
10μM) for further 2 h.At the end of incubation the BR-containing
medium was discarded and the cells incubated in fresh culture
medium for 24–48 h.
In preliminary experiments, both Hep-2 and Vero cells were
incubated with 10–100μM NaOH for 2 h and then incubated
with fresh medium for 24–48 h to evaluate whether or not this
substance affected viral infectivity.
In selected experiments, performed following protocols 1 and
3, Hep-2 and Vero cells were pre-incubated with the NO synthase
(NOS) inhibitor L-NG-monomethyl arginine citrate (L-NMMA,
1mM) for 1 h and further for 2 h in the presence of BR (10μM)
or BR (10μM)-HSA (20μM).
The number of infected cells were calculated by immunoﬂuo-
rescence as described below.
QUANTIFICATION OF INDIVIDUAL INFECTED CELLS
At the end of the 24 or 48-h incubation, cells werewashedwith PBS
to remove residual culture medium, gently scraped and counted.
Twenty-ﬁve thousand infected cells were seeded on single slide
(four slides for each well) and incubated with anti HSV-1 mon-
oclonal antibody (Imagen Herpes simplex virus direct IF test,
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Dako Cytomation, UK) or Pan-enterovirus antibody blend (PAN
ENTEROBLEND,Light Diagnostics, Temecula,CA,USA) accord-
ing to the manufacturers’ instructions. Immunoﬂuorescence is a
simple and reliablemethod to assess viral infection and is routinely
used to estimate either herpesvirus or enterovirus infectivity (Kle-
spies et al., 1996; Saijets et al., 2003; Copeland et al., 2009; Prichard
et al., 2009). Both total cells and immunoﬂuorescence-positive
cells in each sample were counted in at least ﬁve microscopy ﬁelds
(120–160 total cells and ∼5–140 positive cells per ﬁeld) by two
independent blinded investigators and this latter expressed as per-
centage respect to total cells. The inter-investigator variability rate
of cell count was less than 10%.
MEASUREMENT OF NO
Intracellular NO was detected in Vero cells treated for 2 h with
BR (1–10μM) in 0% FCS MEM by using the ﬂuorescent probe
DAF-FM-DA as previously described (Mancuso et al., 2008).
WESTERN BLOT ASSAY
Conﬂuent Hep-2 andVero cells were lysed in lysis buffer (150mM
NaCl, 50mM Tris–HCl, pH 8, 2mM EDTA, 1mM phenylmethyl-
sulfonyl ﬂuoride, 1μg/ml aprotinin, leupeptin, and pepstatin,
1mM sodium orthovanadate) containing 1% Triton X-100 and
0.1% SDS; lysates were cleared by centrifugation, and equal
amounts of protein (40μg) for each sample were subjected to
SDS-PAGE on 10% gel. Western blot analysis was performed as
previously described (Mancuso et al., 2008) by using primary anti-
bodies (see above) diluted 1:1000 and HRP-conjugated secondary
antibodies as appropriate.
STATISTICAL ANALYSIS
Data are expressed as mean± SEM of (N) individual samples
per group. Statistical analysis was performed using ANOVA com-
bined with Dunnet’s or two-tailed Student’s t -tests for compar-
ison within the same group or two groups, respectively. Dif-
ferences were considered signiﬁcant at P < 0.05. The maximal
inhibitory activity values were calculated and conﬁrmed by non-
linear regression analysis using a Prism 4.0 software (GraphPad
Software).
RESULTS
EFFECTS OF BR OR BR–HSA ON HSV-1 AND EV71 INFECTIVITY
The ﬁrst step was to titrate both HSV-1 and EV71 by the plaque
assay. The titer for HSV-1 was calculated to be 1.3× 107 plaque
forming unit (PFU)/ml whereas for EV71 was 1× 109 PFU/ml. At
these titers both HSV-1 and EV71 completely detached the Hep-2
and Vero cell monolayers as early as 24 from infection and this
did not allow us to carry out any experiment to prove the possible
protective effect of 1–10μM BR. For this reason, in all the exper-
imental protocols described below, cells were infected with either
HSV-1 or EV71 at the titer 1× 105 PFU.
In preliminary experiments, the unspeciﬁc effects of NaOH, the
vehicle for BR, on viral replication was studied. Sodium hydroxide
in the range 10–100μM (i.e., the concentrations in 1–10μM BR)
did not have any signiﬁcant effect on HSV-1 or EV71 infectivity at
24–48 h of incubation (data not shown).
Protocol 1
As shown in Figure 1, Hep-2 andVero cells pre-incubated with BR
(1–10μM) for 2 h and then infected with HSV-1 and EV71, were
markedly resistant to the lethal effect of both the viruses and the
percentage of infected cells were signiﬁcantly reduced both at 24
and 48 h after infection (Figure 1). However, in this experimental
setting BR was slightly more efﬁcacious against HSV-1 than EV71
at 48 h from infection (mean maximal inhibitory activity 95 and
83%, respectively) whereas the efﬁcacy at 24 h was comparable. It
is noteworthy to mention that BR displayed a greater potency in
inhibiting both HSV-1 and EV71 infectivity at 24 h than at 48 h
from the infection.
Protocol 2
When HSV-1 and EV71 were pre-incubated with BR (1–10μM)
aloneor complexedwithHSA (20μM) for 2 h and then transferred
FIGURE 1 | Effect of bilirubin (BR) on herpes simplex virus type 1
(HSV-1) and enterovirus EV71 replication. Hep-2 (A) and Vero (B) cells
were pre-incubated with BR (1–10μM) for 2 h. At the end of incubation, BR
was removed and Hep-2 and Vero cells infected with HSV-1 and EV71,
respectively, both at the titer 1×105 PFU. After 2 h, the inocula were
removed and the cells incubated in culture medium for 24 (white columns)
or 48 h (black columns). Data are expressed as the percentage of infected
cells, mean±SEM of six individual samples per group. *P <0.05 and
**P <0.01 versus control (C) after 24 h from infection; ˚P <0.05 and
˚˚P <0.01 versus control after 48 h from infection.
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onto Hep-2 and Vero monolayers, the bile pigment signiﬁcantly
inhibited viral infectivity (Figure 2). In particular, BR alone exhib-
ited lower efﬁcacy against HSV-1 than EV71 at 24 h from infection
(mean maximal inhibitory activity 98 versus 82%, respectively)
whereas at 48 h the efﬁcacy was comparable. Furthermore, the
complexation with HSA did not alter the efﬁcacy of BR against
HSV-1 and EV71 at shorter time from infection whereas reduced
the efﬁcacy after 48 h (mean maximal inhibitory activity 54 versus
82%, respectively).Moreover, the complexationwithHSA reduced
the potency of BR to block HSV-1 replication after 24 h from
infection.
Protocol 3
In Hep-2 andVero cells treated with BR (1–10μM) alone or com-
plexedwithHSA (20μM) and concomitantly infectedwithHSV-1
FIGURE 2 | Direct effect of bilirubin (BR) and albumin-bound bilirubin
(BR–HSA) on herpes simplex virus type 1 (HSV-1) and enterovirus EV71
and how this affects viral replication. Both HSV-1 and EV71 (1×105 PFU)
were pre-incubated with BR (1–10μM) alone or complexed with saturating
HSA (20μM) for 1 h and then transferred to Hep-2 (A) and Vero (B) cell
monolayers for the infection. After 2 h, the inocula were removed and the
cells incubated in culture medium for 24 h (white and dashed columns) or
48 h (black and dotted columns). Both dashed and dotted columns refer to
HSA treatment as described in the Section “Materials and Methods.” Data
are expressed as the percentage of infected cells, mean±SEM of six
individual samples per group. *P <0.05 versus control (C) after 24 h from
infection; ** or †P <0.01 versus respective controls after 24 h from
infection; ˚ or #P <0.05 and ˚˚ or ##P <0.01 versus respective controls after
48 h from infection.
andEV71, the linear tetrapyrrole signiﬁcantlymodiﬁed viral infec-
tivity (Figure 3). In details, BR alone showed a comparable efﬁcacy
against HSV-1 and EV71 at both 24 and 48 h. The complexation
with HSA only partially conﬁrmed this trend, since BR exhibited
similar efﬁcacy against HSV-1 and EV71 at 24 h, but a lower efﬁ-
cacy at 48 h of incubation (mean maximal inhibitory activity 62
and 82%, respectively). Similarly to Protocol 2, the complexation
with HSA reduced the potency of BR to block HSV-1 replication
after 24 h from infection.
Protocol 4
When given after viral infection, BR (1–10μM) signiﬁcantly
reduced HSV-1 virulence only within the ﬁrst 24 h from the
infection, whereas after 48 h only the higher concentration was
FIGURE 3 | Effect of bilirubin (BR) and albumin-bound bilirubin
(BR–HSA) given concurrently with herpes simplex virus type 1 (HSV-1)
and enterovirus EV71 and how this affects viral replication. Hep-2 (A)
and Vero (B) cells were exposed to BR (1–10μM) alone or complexed with
saturating HSA (20μM) and concomitantly infected with HSV-1 and EV71
(1×105 PFU) for 2 h. At the end of incubation the inocula were removed
and the cells incubated in culture medium for 24 (white and dashed
columns) or 48 h (black and dotted columns). Both dashed and dotted
columns refer to HSA treatment as described in the Section “Materials and
Methods.” Data are expressed as the percentage of infected cells,
mean±SEM of six individual samples per group. *P <0.05 versus control
(C) after 24 h from infection; ** or †P <0.01 versus respective controls after
24 h from infection; ˚ or #P <0.05 and ˚˚ or ##P <0.01 versus respective
controls after 48 h from infection.
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active (Figure 4). Conversely, BR maintained its antiviral action
against EV71 at both 24 and 48 h from the infection (Figure 4).
INTRACELLULAR MECHANISMS THROUGH WHICH BR COULD EXERT
ITS ANTIVIRAL ACTIVITY
Bilirubin-IX-alpha (1–10μM) stimulated the phosphorylation of
the member of the MAPK family JNK in Hep-2 and Vero cell
lines (Figure 5A and data not shown), but a positive correlation
between BR concentrations and JNK phosphorylation was not
found. The JNK inhibitor SP600125 (10μM) partially reversed
the BR (10μM)-induced block of HSV-1 and EV71 replication in
Hep-2 andVero cells at both 24 and 48 h from infection (protocols
1 and 3), but this result only approached statistical signiﬁcance
(data not shown).
In addition, BR (10μM) increased the production of NO in
Vero cells in a time-dependent manner reaching statistical signif-
icance as early as 2 h after the administration (Figure 5B). The
involvement of BR-dependent generation of NO in the inhibition
FIGURE 4 | Effects of bilirubin (BR) on cell monolayers infected with
herpes simplex virus type 1 (HSV-1) and enterovirus EV71. After 2 h of
infection with HSV-1 and enterovirus (1×105 PFU), Hep-2 (A) and Vero (B)
cell monolayers were treated with BR (1–10μM) for further 2 h. At the end
of incubation the inocula were removed and the cells incubated in culture
medium for 24 (white columns) or 48 h (black columns). Data are expressed
as the percentage of infected cells, mean±SEM of six individual samples
per group. *P <0.05 and **P <0.01 versus control (C) after 24 h from
infection; ˚˚P <0.01 versus control after 48 h from infection.
of viral replication was conﬁrmed in speciﬁc experiments per-
formedby incubatingHep-2 andVero cellswith L-NMMA(1mM)
1 h before and then in the presence of BR (10μM,2 h) as described
in protocol 1. These experiments demonstrated that the inhi-
bition of NOS activity reversed the BR-induced block of viral
replication in HSV-1 and EV71 after 24 h and 48 h from infec-
tion (Figure 6). A similar degree of inhibition of viral replication
was found when HSV-1 and Vero cells were pre-incubated with
L-NMMA for 1 h and then exposed simultaneously to BR alone or
complexed with HSA plus HSV-1 or EV71 according to protocol
3 (data not shown). This effect of BR was comparable at both 24
and 48 h from infection (data not shown).
DISCUSSION
Over the last years, several studies reported on the microbici-
dal activity of HO-1 and its by-products. Biliverdin-IX-alpha was
shown to inhibit the replication of HCV, HHV-6, and HIV (Mori
et al., 1991; Nakagami et al., 1992; Lehmann et al., 2010; Zhu et al.,
2010),COreduced the growthof E. coli,P. aeruginosa, and S. aureus
(Nobre et al., 2007, 2009;Davidge et al., 2009;Desmard et al., 2012)
and iron almost completely decreased HCV core mRNA and pro-
tein (Hou et al., 2009). The results shown in this paper provided
original evidence about the antiviral role of BR, the formation
of which requires the concerted action of both HO and BVR,
FIGURE 5 | Effect of bilirubin (BR) on cellular expression of the c-Jun
N-terminal kinase (JNK) and nitric oxide (NO) production. Hep-2 and
Vero cells were pre-incubated with BR (1–10μM) for 2 h. At the end of
incubation, BR was removed, the Hep-2 cells lysed and assayed for JNK
phosphorylation byWestern Blot (A) as described under the Section
“Materials and Methods.” α-tubulin was used as housekeeping gene to
verify protein equal loading. On the contrary, Vero cells were assayed for
NO production by using the ﬂuorescent probe DAF-FM-diacetate
[DAF-FM-DA, (B)] as described under the Section “Materials and Methods.”
(A) Shows a representative gel. In (B), data are expressed as DAF-FM-DA
ﬂuorescence arbitrary units (A.U), mean±SEM of six individual samples
per group. *P <0.05 versus control (C).
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FIGURE 6 | Effect of bilirubin (BR) plus the nitric oxide synthase
inhibitor L-NG-monomethyl arginine citrate (L-NMMA) on herpes
simplex virus type 1 (HSV-1) and enterovirus EV71 replication. Hep-2
(A) and Vero (B) cells were pre-incubated with 1mM L-NMMA for 1 h and
then with L-NMMA plus 10μM BR for further 2 h. At the end of incubation,
the medium containing L-NMMA plus BR was removed and Hep-2 and Vero
cells infected with HSV-1 and EV71 (1×105 PFU), respectively. After 2 h, the
inocula were removed and the cells incubated in culture medium for 24
(white columns) or 48 h (black columns). Data are expressed as the
percentage of infected cells, mean±SEM of six individual samples per
group. **P <0.01 versus respective controls (C) and ˚P <0.05 and
˚˚P <0.01 versus 10μM BR after 24 h (white columns) and 48 h (black
columns) from viral infection.
thus expanding the cytoprotective role of this linear tetrapyrrole.
However, in order to appreciate the novelty of our study, some
considerations about the pathophysiology of the HO/BVR system
are needed.
Although HO-1 is considered ubiquitous, this isoform is abun-
dantly expressed in liver, spleen, heart, kidney, and selected brain
regions and its activity increases greatly under stressful condi-
tions (Maines, 1997). On the contrary, the constitutive HO-2
isoform prevails in neurons and testicular germ cells (Maines,
1997). Almost all organs retain BVR activity which transforms BV
into BR (Maines, 1997, 2005). That said, it is plausible to wonder
whether or not the antiviral activity of BV against HHV-6, HIV,
or HCV (Mori et al., 1991; Nakagami et al., 1992; Lehmann et al.,
2010; Zhu et al., 2010) should be attributable to its conversion into
BR by the MT-4 or Huh cells used in those studies rather than a
distinct effect of BV. The lack of inactivation of HHV-6 virions by
BV and the consequent reduced antiviral effect lend support to this
hypothesis. Another concern raised from the studies by Nakagami
et al. (1992) and Mori et al. (1991) is related to the concentrations
of BV used to inhibit HHV-6 andHIV replication. In these studies
the antiviral effect of BV was observed at concentrations ranging
from 10 to 66.7μg/ml, equivalent to ∼17 and 113μM, respec-
tively, two values much higher than those expected to be produced
by the HO activity in humans (Coburn, 1970). These potential
biases were overcome in our study which demonstrated a direct
antiviral effect for BR, the stable end product of heme metabo-
lism, at concentrations from 1 to 10μM which are very close to
those found in human plasma (Berk et al., 1969; Bloomer et al.,
1971) and about 1 order of magnitude lower than those previously
used to demonstrate the antiviral effect of BV. From the analysis
of the pharmacodynamic data, it emerges a different sensitivity of
HSV-1 and EV71 to both free and albumin-bound BR under the
various experimental conditions. A careful comparative evalua-
tion of the mechanisms which underlie the ability of BR to inhibit
HSV-1 and EV71 infectivity under the conditions which charac-
terized Protocols 1–4, is out of the scope of this paper. However, it
is important to highlight that, in this study, both BR and BR–HSA
signiﬁcantly inhibited the infectivity of both HSV-1 and EV71 in
all the experimental settings well within the range of physiologic
concentrations. A preliminary conclusion drawn from our results
was that BR was much more efﬁcacious to inhibit viral infectivity
after 24 h from infection and, in particular, when the bile pigment
was complexed to HSA.
The results shown in this study suggest that BR reduce viral
replication by acting at several stages. The ability of BR to decrease
HSV-1 and EV71 infectivity if pre-incubated with Hep-2 andVero
cells (Figure 1) resembles the pathophysiologic condition inwhich
a virus infects cells endowed with high concentration of BR (e.g.,
hepatocytes, neurons). This ﬁnding is clinically relevant because
nervous system and liver are both target organs for HSV-1 and
enterovirus. Taking into consideration that there is not a direct
clinical evidence of a reduced incidence of viral diseases in subjects
affected by conditions characterized by unconjugated hyperbiliru-
binemia, such as Gilbert’s syndrome (Hirschﬁeld and Alexander,
2006), we hypothesize a protective role for BR in viral diseases in
analogy with the well known protective effect of the bile pigment
against respiratory diseases and cardiovascular accidents (Vitek
et al., 2002; Horsfall et al., 2011). With regard to the inhibition of
viral infectivity by both BR and BR–HSA pre-incubated directly
with virions (Figure 2), it recalls the pathophysiologic condition in
which a virus comes in contact with BR or BR–HSA in the blood,
as during the viremic phase, and then infects tissues. Similarly,
both BR and BR–HSA reduced viral replication if given cells con-
comitantly with HSV-1 and EV71 (Figure 3) and this mimics the
pathophysiologic condition in which a virus comes in contact with
BR/BR–HSA and cells at the blood/tissue interface. However, it is
well known that both herpesviruses and enteroviruses have a short
viremic phase since they colonize target organs very fast and, there-
fore, the potential clinical importance of both these mechanisms
is limited to severe diseases characterized by long-lasting veremic
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phase such as in immunocompromised patients (Stanberry et al.,
1994). Finally, BR was efﬁcacious in reducing viral infection even
when administered to Hep-2 and Vero cells already infected by
HSV-1 and EV71, respectively (Figure 4). This experimental con-
dition reminds of the clinical situation in which jaundice is sec-
ondary to a viral infection, such as hepatitis. As a matter of fact, in
viral hepatitis unconjugated BR increases when hepatic function
decreases under a critical threshold and it is very often accom-
panied by hypoalbuminemia and hypoﬁbrinogenemia and these
alterations represent a life-threatening condition. The possible
protective effect of BR at this stage is, therefore, unlikely.
Overall speaking, the mechanisms involved in the antiviral
activity of BR within the cell or at the interface blood/tissue could
be related either to the stimulation of intracellular pro-survival
pathways, such as the MAPK system, or the production of micro-
bicidal molecules such as NO. The BR-induced stimulation of
NO release in Vero cells (Figure 5) should be considered as one
of the main mechanisms involved in the antiviral effect of the
linear tetrapyrrole against both HSV-1 and EV71. The impor-
tance of NO to decrease HSV-1 and EV71 infectivity was also
corroborated by the evidence that the blockade of NOS, by the
inhibitor L-NMMA, reverted the reduction of viral infectivity due
to 10μM BR (Figure 6). This result is not surprising and is in
good agreement with previous studies which demonstrated the
virucidal effect of NO (Croen, 1993; Akaike and Maeda, 2000).
The JNK signaling cascade is also a crucial effector of the antivi-
ral immune response in inﬂuenza virus (Hrincius et al., 2010),
but there are no data in favor of a cytoprotective effect against
HSV-1 or EV71. The lack of a positive correlation between BR
concentrations and JNK phosphorylation (Figure 5A, in partic-
ular the 55-KDa isoform) could be explained keeping in mind
that the bile pigment was used within the range 1–10μM. It is
interesting to recall that higher concentrations of BR (50μM)
were necessary to clearly stimulate the phosphorylation of MAPK
members including JNK (Fernandes et al., 2007). In addition, the
lack of any signiﬁcant effect of the JNK inhibitor SP600125 (data
not shown) on HSV-1 and EV71 infectivity lends support to the
hypothesis that this pathway is not so efﬁcacious to prevent viral
infection as NO production. The parallel antiviral activity of BR
against HSV-1 and EV71, characterized by important differences
in terms of virion structure, a DNA-containing core surrounded
by an envelope in HSV-1 and a RNA-containing core within a
capsid without envelope in EV71, suggests that BR acts directly
on the virion particles or on nucleic acids. In this light, some
studies reported on a toxic effect of BR, in the presence of tran-
sition metals, on nucleic acids (Asad et al., 1999). Furthermore,
the lack of direct antiviral activity of BV on HHV-6 and HSV-1
(Nakagami et al., 1992) vis-à-vis with the efﬁcient antiviral effect
of BR against HSV-1 and EV71, implies an important role of
the C-10, in analogy with previous results. The absence of dou-
ble bonds at the γ-bridge (which includes C-10) stabilizes the
structure of BR and increases its liposolubility with respect to BV.
Moreover, the C-10 can undergo redox modiﬁcations under con-
ditions of oxidative stress (Stocker et al., 1987a; Baranano et al.,
2002). According to this hypothesis, free radicals could oxidize
protein-bound BR at the C-10 generating BV which, in turn, is
quickly reduced back to BR by the ubiquitous BVR (Baranano
et al., 2002). However, this hypothesis is still debated in the scien-
tiﬁc community (Maghzal et al., 2009), but it cannot be excluded
to explain the antiviral effect of BR toward both HSV-1 and
EV71.
In conclusion, the results in this paper provide the ﬁrst evi-
dence, to our knowledge, of a virucidal effect of BR against HSV-1
and EV71. The implication of these results for the development
of new antiviral drugs designed to modulate the HO/BVR system
are profound and research on these subjects is ongoing in our
laboratories.
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